Somapacitan (Sogroya, Novo Nordisk) is indicated 'for the replacement of endogenous growth hormone (GH) in children aged 3 years and above, and adolescents with growth failure due to growth hormone deficiency (paediatric GHD), and in adults with growth hormone deficiency (adult GHD)'.
The dosage schedule is available in the summary of product characteristics for somapacitan.
The list prices (excluding VAT; BNF online accessed February 2025) are:
£285.45 per 1.5‑ml vial containing 10 mg somapacitan
£428.18 per 1.5‑ml vial containing 15 mg somapacitan.
At the recommended dose of 0.16 mg/kg/week, the annual treatment cost for a person weighing 40 kg is £9,500.
The company has agreed a nationally available price reduction for somapacitan with the Medicines Procurement and Supply Chain. The prices agreed through the framework are commercial in confidence.
For information, the Carbon Reduction Plan for UK carbon emissions is published in Novo Nordisk's carbon reduction plan (PDF).